SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley ...
Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...
Please provide your email address to receive an email when new articles are posted on . Approximately 5,000 people in the United States have Friedreich’s ataxia. Advocates virtually met with ...
Hosted on MSN
Understanding ataxia from genes to daily life
Ataxia is more than just clumsiness—it’s a neurological condition that affects coordination, balance, speech, and even vision ...
The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting Quince Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results